



Versartis
Investor Relations Department
4200 Bohannon Drive
Suite 250
Menlo Park, CA 94025
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VSAR

Last Trade:	2.25
Trade Time:	4:00 PM ET Dec 8, 2017
Change:	0.00 (0.000%)
Day Range	2.20 - 2.30
52-Week Range	1.60 - 24.00
Volume	677,580

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


Company Profile

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry.

Somavaratan (VRS-317) is an investigational, novel, long-acting form of recombinant human growth hormone (rhGH) initially in development for the treatment of GHD in children and adults.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 26, 2017

[Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)

Oct 26, 2017

[Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions](#)

Sep 21, 2017

[Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint](#)

Sep 7, 2017

[Versartis' Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017](#)

Sep 5, 2017

[Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 10, 2017

[Annual Report \(10-K\)](#)

Aug 14, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)